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Autoimmune diseases are a diverse group of chronic disorders and affect a multitude 
of organs and systems. However, the existence of common pathophysiological mech-
anisms is hypothesized and reports of shared risk are emerging as well. In this regard, 
patients with multiple sclerosis (MS) have been shown to have an increased susceptibility 
to develop chronic autoimmune thyroid diseases, in particular Hashimoto’s thyroiditis 
(HT), suggesting an autoimmune predisposition. However, studies comparing such
different pathologies of autoimmune origin are still missing till date. In the present study, 
we sought to investigate mechanisms which may lead to the frequent coexistence of MS 
and HT by analyzing several factors related to the pathogenesis of MS and HT in patients 
affected by one or both diseases, as well as in healthy donors. In particular, we analyzed 
peripheral blood mononuclear cell gene-expression levels of common candidate genes 
such as TNFAIP3, NR4A family, BACH2, FOXP3, and PDCD5, in addition to the regu-
latory T cell (Treg) percentage and the 25-hydroxy vitamin D serum levels. Our findings 
support the plausibility of the existence of common deregulated mechanisms shared by 
MS and HT, such as BACH2/PDCD5-FOXP3 pathways and Tregs. Although the biolog-
ical implications of these data need to be further investigated, we have highlighted the 
relevance of studies comparing different autoimmune pathologies for the understanding 
of the core concepts of autoimmunity.
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inTrODUcTiOn
In recent years, there has been an extensive search for pathophysiological mechanisms that may 
underlie autoimmunity resulting in the frequent co-occurrence of autoimmune disorders (ADs) 
such as multiple sclerosis (MS) and Hashimoto’s thyroiditis (HT) among others (1–5). MS is the 
most common AD of the central nervous system (CNS) involving deregulated immune activation 
(6). HT, characterized by antithyroid autoantibodies in the serum, such as antithyroglobulin (Tg) 
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and antithyroperoxidase (TPO), along with lymphocyte infiltra-
tion of the gland, is the most frequent endocrine disease and 
the most common autoimmune thyroid disease (7, 8). Several 
studies have suggested genetic, epigenetic, environmental, and 
infectious agents as interacting factors influencing the risk for 
the development of these disorders. Nevertheless, the etiology of 
both these diseases is still largely unknown and the pathological 
mechanisms responsible for their co-occurrence remain poorly 
understood.
There have been reports hypothesizing shared risk (9, 10) 
and increased statistical susceptibility for people with one AD 
to develop another, suggesting the concept of an autoimmune 
predisposition (10–12). In the present study, we sought to 
investigate the underlying mechanisms that may lead to this 
phenomenon of poly-autoimmunity in patients with MS and HT.
Genome-wide association studies (GWAS) have identified 
hundreds of risk loci for autoimmunity till date (13). Although 
most of the associations have been linked to classical HLA 
alleles, non-HLA genes have also been demonstrated to con-
tribute to AD susceptibility (13). Among these, genetic variants 
involved in the regulation of NF-kB pathway such as TNFAIP3 
and NR42A are prominent risk factors for MS. Enhanced NF-kB 
activation and greater responsiveness to inflammatory stimuli 
is an important aspect of MS pathology wherein these genes 
may play a role (14, 15). Previous studies by our group have 
demonstrated a marked decrease in gene-expression levels of 
both these NF-kB inhibitors in whole blood and peripheral 
blood mononuclear cells (PBMCs) of MS patients compared 
with healthy controls (HCs) (16–19). Polymorphisms in the 
TNFAIP3 locus are associated with other ADs as well (20) and 
cell-specific TNFAIP3 deletion in mice triggers inflammatory 
phenotypes mimicking those seen in the genetically associated 
ADs (21). The other candidate gene, the nuclear receptor NR4A2, 
together with the other members of the NR4A family (NR4A1 
and NR4A2), promotes the expression of the transcription 
factor FOXP3 and the generation of regulatory T cells (Tregs) 
(22, 23). The deletion of NR4A in mice causes massive multi-
organ inflammation, partially regenerating the phenotype 
observed in human ADs (22).
Apart from these disease-specific risk factors, there are com-
mon genetic loci shared between MS and other ADs including 
HT (14, 24). The Treg-modulating transcription factor BACH2 
is one such common gene that stabilizes Treg development and 
is essential for suppression of lethal inflammation (25). Although 
BACH2 has not been shown to be directly involved in NF-kB 
pathway, its expression is regulated by the NF-kB subunit c-Rel 
(26). Notably, BACH2 transcript levels are decreased in whole 
blood of MS patients compared with HC (27).
In contrast to the wealth of information available from GWAS 
related to MS, specific GWAS conducted on large cohorts of 
patients with HT are lacking. Nevertheless, GWAS in patients 
with autoimmune thyroid disease or hypothyroidism have been 
undertaken that provide insights into the disease (28). Inter-
estingly, these studies show certain common candidate genes that 
maybe shared between HT and MS. Susceptibility to HT has been 
associated with single-nucleotide polymorphisms in the NF-kB 
subunit NFKB1 (29). Also, TNFAIP3 has been detected among 
the susceptibility loci for Graves’ Disease, an autoimmune thyroid 
disease characterized by hyperthyroidism (30, 31). Moreover, 
BACH2 has been described as an autoimmune thyroid disease-
associated region (24), together with another key gene involved 
in the development of Tregs, such as FOXP3 (32, 33).
Treg modulation is important in the pathogenesis of both MS 
and HT. As suggested by experimental evidences and genetic 
associations, most autoimmune conditions are characterized 
by an altered balance between effector and Tregs, with the 
latter having lost the ability to maintain immune tolerance to 
self-antigens (34). The molecular mechanisms involved in the 
development and maintenance of Tregs have been extensively 
investigated and several genes controlling their differentiation 
and function have been identified. Reduced number and/
or function of Tregs have been observed in both MS and HT 
(35–44), although their precise role is still matter of debate. 
However, the deregulation of some of the genes involved in Treg 
modulation, such as NR4A2, BACH2, FOXP3, and PDCD5, 
have been directly associated with the pathogenesis of MS or 
HT (14, 16–18, 24, 27, 45–49).
Here, insufficient vitamin D levels have been shown to con-
tribute to Treg modulation and AD susceptibility as well. Several 
studies demonstrate that vitamin D modulates cell-mediated 
immune responses, suppressing inflammatory T-cell activity, 
and promoting Treg induction (50–52). Furthermore, mounting 
epidemiological evidence suggests an association between vita-
min D deficiency and a higher incidence of autoimmune diseases, 
including MS and HT (53).
Despite this background, a thorough understanding of the 
pathophysiological mechanisms that may underline poly- 
autoimmunity is still missing. In the present study, we investi-
gated factors demonstrated to be involved in the development 
of MS and HT that are frequently coexisting ADs. In particular, 
we analyzed PBMC gene-expression levels of common candidate 
genes such as TNFAIP3, NR4A family, BACH2, FOXP3, and 
PDCD5, in addition to the Treg percentage and the 25-hydroxy 
(25-OH) vitamin D serum levels. To the best of our knowledge, 
this is the first study directly comparing these two pathologies 
that may contribute to the understanding of poly-autoimmunity. 
Here, we sought to investigate if differential breakdown of similar 
anti-inflammatory mechanisms could contribute to the distinct 
levels of inflammation seen in patients with MS, HT, or both. This 
data may also explain if having a greater deregulation puts the 
patient at a higher risk for developing poly-autoimmunity.
MaTerials anD MeThODs
Patients and controls
This study was carried out in accordance with the recommenda-
tions of the Declaration of Helsinki. The protocol was approved 
by the local Ethics Committee of University Hospital San Luigi 
Gonzaga, Piedmont region (18/01/2013 N.20). All subjects gave 
written informed consent.
For this study, 55 treatment-naïve patients diagnosed 
with HT were selected among patients followed up at the 
Struttura Complessa of Endocrinology of the Presidio Sanitario 
TaBle 1 | Demographical and clinical characteristics.
hc (n = 59) hTe (n = 34) hTi (n = 21) hT (n = 55) Ms (n = 59) Ms-hT (n = 13) p-value
Female, n (%) 45 (76) 27 (79) 17 (81) 44 (80) 40 (68) 11 (85) ns
Age, median (range) 42 (22–79) 43.5 (21–75) 51 (23–72) 47 (21–75) 35 (15–65) 39 (27–58) 0.001
TSH, median (range) 1.41 (0.51–4.60) 1.99 (0.62–4.30) 6.6 (4.65–62.30) 3.73 (0.62–62.30) 1.43 (0.43–4.07) 1.74 (0.02–5.47)
AbTPO, median (range) 0.4 (0.1–16.3) 168.2 (0.4–5,677) 448 (0.2–6,500) 244 (0.2–6,500) 0.4 (0.0–9.2) 90.1 (20.1–1,266.9)
AbTG, median (range) 0.3 (0–7.8) 22.5 (0–7,537) 50 (0.3–2,462) 35 (0–7,537) 0.3 (0–4.9) 2.7 (0.3–59.9)
Disease duration,  
months, median (range)
26 (1–235) 27 (1–235) ns
No. of relapses the year  
before, median (range)
1 (0–2) 1 (0–2) ns
EDSS score, median (range) 1 (0–6) 1 (0–6) ns
HC, healthy controls; HTE, euthyroid patients with Hashimoto’s thyroiditis; HTI, hypothyroid patients with Hashimoto’s thyroiditis; HT, patients with Hashimoto’s thyroiditis; 
MS, patients with multiple sclerosis; MS-HT, patients affected by both multiple sclerosis and Hashimoto’s thyroiditis; TSH, thyroid-stimulating hormone; AbTPO, antithyroperoxidase 
antibodies; AbTG, antithyroglobulin antibodies; EDSS, Expanded Disability Status Scale.
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Gradenigo, Turin. The diagnosis of HT was confirmed by con-
ventional clinical, laboratory, and ultrasonographic findings 
and was defined by the presence of at least one type of antithy-
roid antibody among anti-TPO and anti-TG. HT patients were 
classified, according to the normal laboratory reference values 
of serum thyroid-stimulating hormone (TSH), in 34 euthyroid 
(HTE) (TSH from 0.5 to 4.5  mcU/mL) and 21 hypothyroid 
(HTI) (TSH > 4.5 mcU/mL) patients.
Samples from 59 treatment-naïve patients with a diagnosis of 
relapsing–remitting (RR) MS, according to the revised McDonald 
criteria (54), were provided by the Regional Reference Centre for 
MS (CReSM) Bio-bank, San Luigi University Hospital, located 
at the Neuroscience Institute Cavalieri Ottolenghi, Orbassano. 
These patients did not suffer any exacerbations or received 
corticosteroids during the month before sampling. They were 
negative for the presence of antithyroid antibodies and had 
normal TSH values.
A third group of 13 treatment-naïve RRMS patients diagnosed 
with the co-occurrence of HT (MS + HT) simultaneously accord-
ing to the criteria described above was selected.
Finally, 59 HCs were enrolled as a control group by the two 
centers. They were negative for the presence of antithyroid 
antibodies and had normal TSH values and ultrasonographic 
analysis. Moreover, they had no family history of MS or HT in 
their first-degree relatives.
The following inclusion criteria were adopted for all the groups: 
(1) no signs of acute infection or illness during the month prior 
to blood collection and (2) absence of chronic comorbidities.
Thyroid ultrasonography was performed by an experienced 
radiologist, using a 7-MHz linear and an SSA 770 Aplio scanner 
(Toshiba Medical SystemsCo, Ltd., Tokyo, Japan).
Detailed demographic and clinical features are reported in 
Table 1.
sample collection
Blood collection was done in the morning between 8:30 and 
10:30 a.m. For each subject, 6 mL of whole blood was collected 
in Vacutainers with serum separator and 24 mL in EDTA 
Vacutainers (BD Biosciences, Milan, Italy). After collection, 
samples were immediately processed as follows:
Serum samples were centrifuged for 10  min at 3,000  rcf, 
aliquoted, and stored at −80°C until use. PBMCs were freshly 
isolated by Lymphoprep density-gradient centrifugation accord-
ing to the manufacturer’s instructions. Cells were split in two 
aliquots, both stored at −80°C until use: one was resuspended 
in RNA-Later solution (Thermo Fisher Scientific, Waltham, 
MA, USA) for total RNA extraction and the other was stored 
in a cryopreserving solution containing 30% FBS (Thermo 
Fisher Scientific), 10% DMSO (Sigma-Aldrich, St Louis, MO), 
and 60% RPMI (Thermo Fisher Scientific) for flow-cytometry 
analysis. Whole blood for total RNA extraction was resuspended 
in homogenization buffer (Promega, Monza, Italy) and stored at 
−80°C until use.
serum examination
Serum levels of TSH, anti-TPO, and anti-TG antibodies and 25- 
OH vitamin D were determined at the Analysis Laboratory of 
Gradenigo Hospital in a single analytical session. Determinations 
of TSH levels and antibodies titer were performed by two-site 
quantitative automated immunoenzymatic assays using the 
following kits: Access HYPERsensitive hTSH, Access Thyroglo-
bulin Antibody II, and Access Thyroperoxidase Ab (Beckman 
Coulter). The 25-OH vitamin D levels were determined in all the 
enrolled subjects by chemiluminescence immunoassay using the 
LIAISON 25-OH Vitamin D TOTAL Assay (DiaSorin, Saluggia, 
Italy).
rna extraction and gene-expression 
analysis
Gene-expression analyses were conducted on 34 HTE, 20 HTI, 
22 MS, 7 MS + HT, and 56 HC. Total RNA was extracted using 
the automated Maxwell® Rapid Sample Concentrator (RSC) 
Instrument, with Maxwell® 16 LEV simplyRNA Blood Kit 
(Promega) for whole blood and simplyRNA Tissue kit (Promega) 
for PBMCs, following the manufacturer’s instructions. Total RNA 
was reverse-transcribed at a final concentration of 20 ng/µL using 
High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific). Gene-expression analysis was performed by real-time 
PCR using TaqMan® gene-expression products (Thermo Fisher 
Scientific). Expression levels of target genes were calculated by 
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the normalized comparative cycle threshold (Ct) method (2−ΔΔCt), 
using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
as reference gene and the Universal Human Reference RNA 
(Stratagene, Santa Clara, CA, USA) as calibrator.
Flow cytometry
Regulatory T-cell levels were evaluated in 29 HTE, 17 HTI, 22 
MS, 12 MS +  HT, and 33 HC. After gentle thawing at 37°C, 
PBMCs were immediately added to 5-mL RPMI 1640 (Thermo 
Fisher Scientific), supplemented with 10% FBS (Thermo Fisher 
Scientific) and centrifuged to remove DMSO (Sigma-Aldrich). 
Samples were resuspended in RPMI 1640 medium supplemented 
with 10% heat-inactivated FBS and counted for flow-cytometry 
experiments.
For Treg evaluation, PBMCs were incubated for 5 min at 4°C 
with rabbit immunoglobulins G (IgG, Sigma-Aldrich) to block 
non-specific sites and then for 10 min at 4°C with fluorochrome-
conjugated monoclonal Ab (mAb) or isotype-matched negative 
controls. For Treg determination the following antihuman 
mAbs were used: CD4 PE-Vio770, CD25 APC, and CD127 
FITC (Miltenyi Biotec, Bergisch Gladbach, Germany). Living 
cells identified by propidium iodide (Sigma-Aldrich) exclusion 
were gated according to their light-scatter properties to exclude 
cell debris. Samples were analyzed using a CyAn ADP, running 
Summit 4.3 software (Beckman Coulter, Brea, CA, USA).
statistical analysis
Continuous data are presented as medians and ranges and 
discrete data are given as counts and percentages. Fisher’s exact 
tests were performed to compare groups of categorical data. 
Mann–Whitney U test and Kruskal–Wallis with Dunn’s posttest 
with false discovery rate (FDR) correction method were used to 
compare medians between groups of continuous data, as appro-
priate. The correlation between gene expression, vitamin D, Treg 
levels, and clinical and demographical variables was assessed by 
Pearson’s or Spearman’s correlations, as appropriate. These vari-
ables have been described in Table 1: (1) sex and age at sampling, 
TSH, anti-TPO, and anti-TG Ab levels for all the groups and (2) 
disease duration, number of relapses 1 year before sampling and 
EDSS score at sampling for MS and MS + HT groups. Statistical 
significance was considered at p ≤ 0.05. All analyses were carried 
out using R version 3.1.1 (www.r-project.org).
resUlTs
Demographic and clinical data of all subjects are summarized 
in Table  1. There was no difference observed in the gender 
distribution between groups. The median age of the MS group 
was significantly lower compared with HC, the, and HTI (Dunn’s 
posttest with FDR correction, p = 0.03, p = 0.01, and p = 0.002, 
respectively) which is likely due to the difference in the age of 
onset of the two diseases (6, 8).
Notably, the median disease duration of MS and MS +  HT 
patients (defined as the time from the onset of the first disease 
symptoms to blood sampling) was just over 2  years, because 
patients were selected among those who had just received the MS 
diagnosis and had not yet started disease-specific therapies.
Differential expression levels of 
candidate genes among study groups
To investigate the deregulated mechanisms possibly shared by 
MS and HT, we measured the PBMC gene-expression levels of 
a panel of key molecules (i.e., TNFAIP3, NR4A family, BACH2, 
PDCD5, and FOXP3) in all study groups through real time PCR. 
Notably, the gene expression of the whole panel was first compared 
between HTE and HTI. If no differences were revealed, they were 
considered as a single HT group for subsequent analyses for that 
particular gene.
We found that TNFAIP3 gene expression was lower in MS 
compared with both HC and HT groups (Mann–Whitney 
U test, p = 0.04 and p = 0.005, respectively). A similar downregu-
lation was found also for MS + HT patients, but it did not reach 
statistical significance (Figure 1A, right panel). On the contrary, 
HT patients did not show a downregulated gene expression. 
No significant differences were found between HTE and HTI 
(Figure 1A, left panel).
In the NR4A family, NR4A1 transcript level was similar 
among all groups (Figure 1B), while NR4A2 was underexpressed 
in MS compared with both HC and HT (Mann–Whitney U test, 
p = 0.03 and p = 0.002, respectively) (Figure 1C, right panel), 
corroborating previous studies (17, 18). NR4A3, however, was 
expressed at a higher level in HTI compared with HTE and HC 
(Mann–Whitney U test, p = 0.0006 and p = 0.001, respectively) 
(Figure 1D). Notably, a decreased expression of both genes was 
also found in MS + HT patients compared with HC.
The next candidate gene, BACH2, was overexpressed in HT, 
MS, and MS + HT compared with HC (Mann–Whitney U test, 
p = 0.01, p = 0.0006, and p = 0.005, respectively) (Figure 1E, 
right panel). No significant differences were found between 
HTE and HTI forms (Figure  1E, left panel). These data are 
in contrast with previous results obtained in our laboratory 
on whole blood, demonstrating a downregulation of BACH2 
gene expression in therapy-naïve MS patients as compared 
with HC (27). To reproduce the same experimental condi-
tions as before, we repeated the measurement on whole blood 
obtained from the same individuals enrolled in the study. 
In this case, BACH2 was underexpressed in MS compared 
with both HC and HT (Mann–Whitney U test, p = 0.04 and 
p = 0.002, respectively) (Figure 1F, right panel), confirming 
previous data.
On the other hand, PDCD5 gene was found to be differently 
expressed in HTE and HTI groups. HTI and MS patients showed 
higher PDCD5 levels compared with both HC (Mann–Whitney 
U test, p = 0.005, and p = 0.006, respectively) and HTE (Mann–
Whitney U test, p = 0.0003 and p = 0.0001, respectively). The gene 
was expressed at higher levels also in MS + HT patients compared 
with HTE (Mann–Whitney U test, p = 0.008) and HC, although 
the latter did not achieve statistical significance (Mann–Whitney 
U test, p = 0.06) (Figure 1G).
FOXP3 gene was overexpressed in HT, MS, and MS +  HT 
compared with HC (Mann–Whitney U test, p = 0.01, p = 0.04, 
and p = 0.002, respectively), with the MS + HT group expressing 
the highest levels (Mann–Whitney U test, p = 0.008 and p = 0.03 
for comparisons with HT and MS, respectively) (Figure 1H, right 
panel). No significant differences were found between HTE and 
FigUre 1 | Peripheral blood mononuclear cell (PBMC) gene-expression levels of (a) TNFAIP3, (B) NR4A1, (c) NR4A2, (D) NR4A3, (e) BACH2, (g) PDCD5, and 
(h) FOXP3, and (F) whole peripheral blood gene-expression level of BACH2. Relative expression was calculated by the normalized comparative cycle threshold 
method (2−ΔΔCt) and differences between groups were evaluated by the Mann–Whitney U test.
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HTI, although FOXP3 levels in the HTI group appeared to be 
higher (Figure 1H, left panel). A significant correlation between 
BACH2 and FOXP3 levels was found in the overall population 
and in HC, HT, and MS separately (Pearson’s correlation, r = 0.62 
and p < 0.0001 for the overall population; r = 0.73 and p < 0.0001 
for HC; r = 0.40 and p = 0.002 for HT; r = 0.60 and p = 0.004 
for MS) (Figures 2A–E). Similarly, a significant, although weaker, 
correlation between PDCD5 and FOXP3 levels was found in the 
overall population and in HC, HT, and MS separately (Pearson’s 
correlation, r = 0.39 and p < 0.0001 for the overall population; 
r =  0.30 and p =  0.02 for HC; r =  0.34 and p =  0.01 for HT; 
r =  0.56 and p =  0.007 for MS). In particular, this correlation 
was found in HTE (Pearson’s correlation, r = 0.54 and p = 0.001) 
(Figures 2F–J) but not in HTI (data not shown).
Treg Deficiency affecting Multiple 
sclerosis (Ms) Patients to a greater 
Degree as compared with hashimoto’s 
Thyroiditis
In order to evaluate possible deregulation of Treg number 
in the patient groups of this study, the percentage of this 
key regulatory cell population (identified as cells marked by 
CD4+CD25highCD127− as proposed by the Immunophenotyping 
Consortium) (55) was measured in PBMCs by flow-cytometry 
analysis. We observed reduced Treg levels in the MS group com-
pared with all other groups (Mann–Whitney U test, p < 0.0001, 
p = 0.002, and p < 0.0001 for HT, MS + HT, and HC, respectively) 
and in the HT group compared with HC (Mann–Whitney U test, 
p = 0.04) (Figure 3B). No differences were found between HTE 
and HTI (Figure 3A).
No correlations between gene-expression levels and Treg 
percentage were found (data not shown).
25-Oh Vitamin D levels significantly 
reduced in Ms Patients
In order to evaluate a possible association of vitamin D levels 
and the ADs analyzed here, serum levels of the active metabolite 
25-OH vitamin D were measured in samples from HC, HT, MS, 
and MS + HT groups. Serum 25-OH vitamin D levels were low 
overall, as only 4% of our study population (two HC, four MS, 
and two HT) reached the sufficiency threshold of ≥30 ng/mL. 
In particular, 23% of HC, 15% of HT, 36% of MS, and 38.5% of 
MS + HT showed a severe deficiency, defined as <10 ng/mL; 49% 
of HC, 52% of HT, 45% of MS, and 38.5% of MS + HT showed 
a moderate deficiency, defined as 10–19.9 ng/mL; 25% of HC, 
29% of HT, 12% of MS, and 23% of MS + HT showed a mild 
deficiency, defined as 20–29.9 ng/mL (Figure 4A). Fisher’s exact 
test did not highlight significant differences between expected 
and observed frequencies for 25-OH vitamin D levels categories 
within groups.
25-Hydroxy vitamin D levels were significantly lower in 
MS compared with both HC and HT (Mann–Whitney U test, 
p = 0.04 and p = 0.02, respectively). Also, in the MS + HT group, 
the 25-OH vitamin D levels seemed to be lower as compared 
with HC and HT, but the difference did not reach statistical 
significance (Figure 4C). No difference was found between HTE 
and HTI (Figure 4B) and no correlation between 25-OH vitamin 
D and Treg or gene-expression levels was highlighted (data not 
shown).
DiscUssiOn
Out of the many different comorbidities that may be observed 
with MS, HT, together with psoriasis, is the most commonly 
reported autoimmune condition in patients and their relatives 
(1–3).
The main purpose of this study was to investigate the pos-
sible common molecular mechanisms underlying MS and HT. 
Additionally, we tried to understand whether a high “degree” 
of autoimmunity, such as that observed in MS patients also 
affected by HT, could be related to a more profound alteration of 
these shared pathological mechanisms. A better understanding 
of these altered mechanisms could provide important insights 
into the etiology and pathogenesis of these disorders along with 
unraveling potential therapeutic targets.
The shared risk of these diseases may reflect common genetic 
susceptibility and/or environmental exposures. Thus, we ana-
lyzed several factors that are known to be associated with the 
pathogenesis of both disorders in patients affected by MS, HT, 
or both.
Notably, this study has strict inclusion criteria to only consider 
patients who are at the beginning of their illness and have not yet 
started specific pharmacological treatment. Therefore, the size of 
the MS + HT group was limited by the difficulty to find patients 
who had already developed HT at the time of MS diagnosis, given 
the different age of onset of the two pathologies. The control group 
has been selected carefully as well. Only individuals who are nega-
tive for antithyroid antibodies, free of any acute or chronic illness 
and with no family history of any of the two diseases have been 
included in the HC. Although it is significantly difficult to obtain 
such ideal cohorts, it is crucial to ensure optimum conditions for 
studying any immunological phenomena, free from the influence 
of therapies. The HT group was further divided in euthyroid 
(HTE) and hypothyroid (HTI) patients according to their TSH 
level, to investigate potential differences between patients with 
subclinical and more severe forms of the disease.
First, we measured the PBMC expression levels of a panel of 
genes that play a key role in the immune system regulation and 
whose altered expression or function have been associated with 
the pathogenesis of one or both the disorders. This panel included 
candidate genes such as TNFAIP3, the NR4A family, BACH2, 
PDCD5, and FOXP3.
TNFAIP3 and the NR4A family, including NR4A1, NR4A2, 
and NR4A3, represent a group of potent inhibitors of NF-kB 
pathway (56, 57), whose deregulation has been associated to 
several chronic inflammatory and autoimmune conditions 
including MS (58, 59). Here, we demonstrate that both TNFAIP3 
and NR4A2 show decreased expression levels in MS patients 
compared with the HC group. These data corroborate previous 
findings by our group obtained on independent cohorts of HC 
and MS (16–19). Conversely, our study did not show an altered 
expression of either TNFAIP3 or NR4A2 in the HT group, 
suggesting that the deregulation of these two NF-kB inhibitors 
FigUre 2 | (a–e) Scatterplots showing the relationship between peripheral blood mononuclear cell (PBMC) gene-expression levels of BACH2 and FOXP3  
in (a) the whole cohort of individuals and in (B) healthy control (HC), (c) Hashimoto’s thyroiditis (HT), (D) multiple sclerosis (MS), and (e) MS + HT separately.  
(F–J) Scatterplots showing the relationship between PBMCs gene-expression levels of PDCD5 and FOXP3 in (F) the whole cohort of individuals and in (g) HC,  
(h) HTE, (i) MS, and (J) MS + HT separately. Linear correlation was evaluated by Pearson’s correlation analysis.
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FigUre 4 | (a) Percentage of individuals for each group showing severe 
25-OH vitamin D deficiency (<10 ng/mL), moderate deficiency (10–19.9 ng/
mL), mild deficiency (20–29.9 ng/mL), or sufficiency (>30 ng/mL). 25-OH 
vitamin D serum levels in (B) hypothyroid (HTI) and HTE separately and in  
(c) healthy control (HC), Hashimoto’s thyroiditis (HT), multiple sclerosis (MS), 
and MS + HT. Differences between groups were evaluated by the Mann–
Whitney U test.
FigUre 3 | Percentage of Tregs, defined as CD4+CD25highCD127− cells,  
in (a) hypothyroid (HTI) and euthyroid patients with Hashimoto’s thyroiditis 
(HTE) separately and in (B) healthy control (HC), Hashimoto’s thyroiditis  
(HT), multiple sclerosis (MS), and MS + HT. Differences between groups  
were evaluated by the Mann–Whitney U test.
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HC, suggesting a major contribution of the MS disease in these 
patients.
The other two members of the NR4A family, namely NR4A1 
and NR4A3, share a high degree of homology in the molecular 
structure, as well as complementary functions with NR4A2 
(60). However, contrary to NR4A2, the gene-expression levels 
of these two nuclear receptors did not show differences between 
groups, except for NR4A3 which was expressed at a higher level 
in HTI compared with HTE and HC. These data may suggest 
a specific deregulation mechanism for NR4A2 in MS and a 
particular function of this gene, which is not compensated by 
the other members of the family.
Similar to TNFAIP3 and the NR4A family, BACH2, PDCD5 
and FOXP3 are among the NF-kB target genes (26, 61, 62). 
Furthermore, BACH2 and PDCD5 have been demonstrated to 
be directly involved in the upregulation of FOXP3 gene expres-
sion and the enhancement of its function, similar to the NR4A 
family (23, 63, 64). Our results indicate that BACH2 and FOXP3 
are upregulated in MS, HT, and MS +  HT compared with HC, 
with the MS + HT group expressing the highest levels. PDCD5 
is upregulated as well in all patient groups in comparison to HC, 
with the exception of HTE patients. In addition, a significant 
correlation of FOXP3 levels with BACH2 and with PDCD5 levels 
was found in HC, MS, and HT groups individually. These data 
suggest that BACH2 and PDCD5 both may play a role to induce 
FOXP3 expression in PBMCs in the two ADs. Given that BACH2, 
PDCD5, and FOXP3 are immuno-modulating molecules with a 
major anti-inflammatory and immunosuppressive role (25, 63, 65), 
an increase in their expression levels in both the ADs may appear 
unexpected. However, this could be explained by considering the 
broad spectrum of action of these molecules, as described below.
Our findings show that BACH2 is expressed at different 
levels in whole blood and PBMCs, suggesting that it could play 
different cell-specific roles. For example, BACH2 is essential for 
the development of effector-memory and Tregs (25, 66), B cells 
(67, 68) and alveolar macrophages (69). In addition, new 
evidences suggest its involvement in the homeostasis of granu-
locytes. In particular, a deregulation of BACH2 expression in 
lymphocytes has been proposed to alter the granulocytes balance 
(70), but there are no indications of how it could affect their gene 
expression in the literature.
PDCD5 exerts complex biological functions, some of which 
have not yet been defined. It can accelerate apoptosis in dif-
ferent types of cells in response to various stimuli and control 
autoimmunity via the FOXP3–Tregs axis (61, 63). PDCD5 
transcription and protein activity is enhanced by the NF-kB 
p65 subunit (61). Its abnormal expression has been shown to be 
involved in autoimmune diseases and inflammatory processes. 
For example, similar to our results, PDCD5 levels in serum 
and synovial fluid of rheumatoid arthritis (RA) patients have 
been found to be significantly higher compared with HC, and a 
negative correlation of its levels with disease activity indices has 
been described (71). PDCD5 transcript levels were also found 
to be elevated in the monocytes activated by inflammatory 
stimuli (72), in HIV-infected individuals (73) and in patients 
with chronic liver diseases (74). Furthermore, apoptosis is one 
of the processes used by organisms to counteract the aberrant 
might be an MS-specific pathogenic mechanism. Although it 
did not reach statistical significance, a decreased expression of 
both genes was also found in MS + HT patients compared with 
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survival of autoreactive lymphocytes (75) and is crucial in the 
pathogenesis and the development of hypothyroidism (7). 
In this context, our findings suggest that elevated PDCD5 levels 
in MS and HT could represent a defense mechanism aimed at 
eliminating auto-reactive immune cells characterized by an 
“apoptosis-resistant” behavior. The increased PDCD5 expression 
in patients with hypothyroidism as well may reflect the enhanced 
apoptotic processes in these patients.
The last candidate gene, transcriptional regulator FOXP3 
is an important determinant of Treg development and func-
tion (65). However, it is also highly expressed by the recently 
activated conventional human T  cells (76, 77). Contrary to 
Tregs which stably express FOXP3, conventional human T cells 
transiently upregulate FOXP3 expression upon in vitro activa-
tion without acquiring suppressive capabilities. This happens 
also in  vivo, especially in individuals with ongoing immune 
responses wherein T cells are chronically stimulated (78), and 
could explain the higher FOXP3 levels we found in our cohorts 
of patients. According to our results, upregulation of FOXP3 
mRNA in peripheral T cells has been associated with HT, inde-
pendent from the thyroid hormone status but proportional to 
disease activity (46). Transcriptional activity of FOXP3 is also 
dependent on its subcellular localization, which differs between 
Tregs and recently activated T cells, with a predominance in the 
nucleus for the former and in the cytoplasm for the latter cell 
population (79). Importantly, whether FOXP3 performs any 
additional effector functions in the cytoplasm which may affect 
patients still needs to be clarified.
According to these evidences, despite the finding of a FOXP3 
overexpression in patients with MS, HT and MS + HT, we found 
decreased Treg levels in MS and HT compared with HC, with 
MS patients showing the lowest percentage. Tregs are a group of 
heterogeneous cells, with functional and phenotypic distinctions 
predicted by their cell surface marker profile. There is still no 
consensus regarding the best markers for human Tregs, thus the 
literature is not consistent with respect to the definitions of Treg 
subsets and their frequency and functions in both diseases (34). 
Nevertheless, a growing body of evidence, as well as recent find-
ings by our group (43), suggest that these cells are numerically 
reduced and/or functionally impaired in MS patients. These cells 
might have a key role in the MS and HT pathogenesis influenc-
ing disease susceptibility and clinical course as well (35–42, 44). 
Interestingly, we found that Treg levels in MS +  HT patients 
are similar to HC and significantly higher compared with MS 
patients. This result is difficult to interpret due to the paucity of 
literature in this field. Annunziata et al. described an inverse cor-
relation between the titer of anti-Tg antibodies and the disability 
score in MS patients, suggesting a possible protective role of these 
antibodies that still needs to be further clarified (80).
Finally, 25-OH vitamin D is thought to modulate cell-mediated 
immune responses and to regulate inflammatory T-cell activity, 
shifting from a T-helper 1 to a Th2 phenotype and skewing away 
from the inflammatory Th17 phenotype. It has been shown to 
promote Treg development and functions as well (50–52). Our 
analysis revealed that the 25-OH vitamin D serum levels in MS 
patients are lower compared with both HC and HT, conforming 
to our findings on Treg levels. These data are also in line with the 
literature, as serum 25-OH vitamin D levels have been described 
to inversely correlate with the likelihood of relapse and disease 
activity on magnetic resonance imaging (81, 82), in addition to 
being associated with a better response to treatments such as 
interferon beta (83).
In conclusion, although very different from each other, MS 
and HT share certain common deregulated anti-inflammatory 
mechanisms, reflecting the autoimmune nature of both these 
disease conditions. However, there are some profound differ-
ences. MS patients are affected by a higher degree of deregulation 
of the analyzed factors compared with the HT group, which may 
indicate a more severe disease phenotype. HTE and HTI patients 
do not show relevant differences, apart from differential expres-
sion of genes implicated in the regulation of apoptosis. Patients 
affected by both diseases tend to have deregulations similar to 
the MS group, except for the Treg frequency, for which the co-
occurrence of HT seems to reduce the defect.
These data, together with evidences from epidemiological and 
association studies, support the existence of shared deregulated 
mechanisms, that are represented here by BACH2/PDCD5-
FOXP3 pathways and Tregs, involved in different extents across 
the spectrum of ADs. The biological implications of these findings 
need to be elucidated. Thus, further studies comparing different 
pathologies of autoimmune origin are vital to understand the core 
concepts of autoimmunity.
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